Roche and Decode Genetics map Alzheimer's gene
Decode Genetics, Reykjavik, Iceland, and Basel, Switzerland-based F. Hoffmann-La Roche Ltd. announced that scientists at Decode have successfully mapped a novel gene that contributes to the occurrence of the common form of Alzheimer's disease.
Decode Genetics, Reykjavik, Iceland, and Basel, Switzerland-based F. Hoffmann-La Roche Ltd. announced that scientists at Decode have successfully mapped a novel gene that contributes to the occurrence of the common form of Alzheimer's disease.
Roche plans to initiate discovery and development programs for new diagnostics and therapeutics building on this genetic information. Decode Genetics has received an undisclosed milestone payment from Hoffman-La Roche for this accomplishment.
"We have made significant progress towards finding a novel gene that, depending on the presence of certain molecular variations, contributes to the common form of Alzheimer's disease," said Kari Stefansson, chief executive officer of Decode Genetics. "This work underscores the feasibility and power of studying common complex diseases using Iceland's unique resources."
Jonathan Knowles, head of global research at Hoffman-La Roche, added, "We are very impressed by the rapid progress made by Decode Genetics towards identifying genes that play important roles in the molecular pathology of common diseases." PR
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
